QURE Stock Fades After AMT-130 filing — But William Blair Sees 58% Upside
uniQure (QURE) filed for U.S. and U.K. approval of its Huntington’s disease gene therapy, AMT-130. William Blair resumed coverage with an Outperform rating and $73 price target, citing a 58% upside. Shares initially rose 6% but closed down 3%. The FDA may grant priority review, potentially cutting the review period. AMT-130, if approved, would be uniQure’s second marketed gene therapy.
How this was made
The 30-second read
Why it matters
The filing reduces regulatory uncertainty and positions QURE for a potential accelerated approval, which could significantly re‑rate the stock.
Market read
Regulatory filing is a primary catalyst for a micro‑cap biotech, likely to attract trader interest and influence sector sentiment.
What to watch
Upcoming four‑year data later this month could alter expectations.
Background
uniQure (NASDAQ:QURE) announced regulatory filings for its AMT-130 gene therapy targeting Huntington's disease, with analyst William Blair resuming coverage.
Ticker impact
uniQure filed a Biologics License Application with the FDA and a marketing authorization in the UK for its Huntington's gene therapy AMT-130.
Stock may rally on the prospect of approval and the 58% upside implied by William Blair.
First filing of a pivotal therapy with breakthrough and RMAT designations; analysts project substantial re‑rating.
Market effects
Highlights progress in gene‑therapy sector and may boost peer biotech valuations.
UK biotech market gains visibility from the MHRA filing.
First potential Huntington's disease therapy could set precedent for rare‑disease gene treatments worldwide.
Counterpoint
Approval risk remains high; FDA may request additional data, delaying upside.
Key entities
- companyuniQure
Biotech firm developing gene therapies, ticker QURE.
- analyst_firmWilliam Blair
Equity research firm that resumed coverage with a 58% upside target.
